Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...
Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive ...
The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...
Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...
But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
A Brussels court is weighing whether Poland must pay Pfizer €1.4 billion for undelivered COVID vaccines, in a case that could ...
KALAMAZOO, Mich. -- Even though U.S. health officials authorized the emergency use of Pfizer's COVID-19 vaccine, getting the pandemic under control will take time and effort. One of the biggest steps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results